BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/11/2016
Entire Document
 

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2016
_______________________

BioLineRx Ltd.
(Translation of Registrant’s name into English)
_______________________

2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☑          Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐          No ☑


 
On August 11, 2016, the Registrant will issue a press release announcing its financial results for the three and six months ended June 30, 2016. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of June 30, 2016, and for the three and six months then ended. Attached hereto are the following exhibits:
 
Exhibit 1: Registrant’s press release dated August 11, 2016;
 
Exhibit 2: Registrant’s condensed consolidated interim financial statements as of June 30, 2016, and for the three and six months and then ended;
 
Exhibit 3 - Registrant’s operating and financial review as of June 30, 2016, and for the three and six months then ended.
 

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  BioLineRx Ltd.  
       
  By: 
/s/ Philip Serlin
 
   
Philip Serlin
 
   
Chief Financial and Operating Officer
 

Dated: August 11, 2016